Experimental maternal phenylketonuria: an examination of two animal models.
Two satisfactory rat models of maternal phenylketonuria (PKU) have been developed. Continuous subcutaneous infusion into pregnant rats from the 9th-20th day of gestation of either (1) phenylacetate (PA), to elevate plasma levels of unconjugated PA to 0.25-0.60 mumol/ml, or (2) a nontoxic dose (0.2 mumol/g/day) of p-chlorophenylalanine (pClPhe) with L-phenylalanine (Phe), to elevate plasma Phe levels at least 10-fold (1.7-2.3 mumol/ml) and unconjugated PA to at least 0.2 mumol/ml, produced the syndrome of untreated maternal PKU: spontaneous abortion, mortality rate greater than normal among the newborn, retarded growth of fetal body and brain, and a learning deficit among the progeny. From the plasma of rats infused with only pClPhe, a metabolite was isolated and identified as p-chlorophenylacetic acid. This compound, at a concentration greater than 0.15 mumol/ml plasma was found to retard fetal body and brain growth. In the pregnant rat, plasma levels of unconjugated PA, in the range observed in some PKU individuals on a normal diet, effectively induced a simulation of maternal PKU. The results of this investigation support our contention that PA, which is produced in excessive amounts in clinical PKU, is the primary cause of the brain dysfunction.
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D010134:Fenclonine / Q000633:toxicity; D006801:Humans; D008431:Maternal-Fetal Exchange; D010648:Phenylacetates / Q000633:toxicity; D010649:Phenylalanine / Q000633:toxicity; D010661:Phenylketonurias / Q000139:chemically induced / Q000150:complications; D011247:Pregnancy; D011248:Pregnancy Complications; D051381:Rats; D011919:Rats, Inbred Strains
D010648:Phenylacetates; D010649:Phenylalanine; C025136:phenylacetic acid; D010134:Fenclonine